Patients with ovarian cancer who begin postoperative adjuvant chemotherapy within 42 days of ending neoadjuvant chemotherapy have superior survival compared to those who initiate therapy after that point.
for trend <.001). Patients in the highest quartile (>50 days) had the highest risks of recurrence (HR, 1.93; 95% CI, 1.16-3.20) and death (HR, 2.06; 95% CI, 1.05-4.02), as compared with patients in the lowest quartile (≤37 days).
Lee YJ, Chung YS, Lee J, et al. Impact of the time interval from completion of neoadjuvant chemotherapy to initiation of postoperative adjuvant chemotherapy on the survival of patients with advanced ovarian cancer [published online November 21, 2017]. Gynecol Oncol doi: 10.1016/j.ygyno.2017.11.023.
... to read the full story